Selection of Streptococcus pneumoniae mutants having reduced susceptibility to moxifloxacin and levofloxacin.
With Streptococcus pneumoniae, moxifloxacin was 4- and 10-fold more effective than levofloxacin at restricting selection of resistant mutants and at killing resistant mutants, respectively. The selection frequency for first-step topoisomerase mutants was 1,000 times lower for moxifloxacin than for levofloxacin; this difference was lost when second-step mutants were selected.
Li
Xinying
X
Public Health Research Institute, New York, New York 10016, USA.
Zhao
Xilin
X
Drlica
Karl
K
D000890:Anti-Infective Agents / Q000494:pharmacology*; D001372:Aza Compounds; D024841:Fluoroquinolones; D064704:Levofloxacin; D008826:Microbial Sensitivity Tests; D000077266:Moxifloxacin; D009154:Mutation; D015242:Ofloxacin / Q000494:pharmacology*; D011804:Quinolines; D013296:Streptococcus pneumoniae / Q000187:drug effects* / Q000235:genetics
D000890:Anti-Infective Agents; D001372:Aza Compounds; D024841:Fluoroquinolones; D011804:Quinolines; D064704:Levofloxacin; D015242:Ofloxacin; D000077266:Moxifloxacin